TBX4 syndrome: a systemic disease highlighted by pulmonary arterial hypertension in its most severe form

Eric D. Austin 1 and C. Gregory Elliott 2

Affiliations: 1Dept of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA. 2Dept of Medicine, Intermountain Medical Center and the University of Utah, Murray, UT, USA.

Correspondence: Eric D. Austin, Dept of Pediatrics, Division of Pulmonary, Allergy, and Immunology Medicine, DD-2205 Medical Center North, Vanderbilt University School of Medicine, Nashville, TN, 37232-2578, USA. E-mail: eric.austin@vumc.org

Thoré and co-workers add to our understanding of TBX4-associated pulmonary vascular disease as a precapillary form of pulmonary hypertension (PH), showing that TBX4 mutations may also cause multisystem anomalies concurrent with, or independent of, PH. [https://bit.ly/2yIqb9v]

Cite this article as: Austin ED, Elliott CG. TBX4 syndrome: a systemic disease highlighted by pulmonary arterial hypertension in its most severe form. Eur Respir J 2020; 55: 2000585 [https://doi.org/10.1183/13993003.00585-2020].

This single-page version can be shared freely online.

Sometimes we miss the “ah-ha” moment, or, at least require multiple reminders to pay attention. This may have been the case for many of us in the pulmonary vascular field regarding rare variants (mutations) in the gene T-box transcription factor 4 (TBX4) and pulmonary hypertension (PH). In 2004, investigators in the Netherlands published the first description of humans with mutations in the T-box transcription factor 4 (TBX4) gene. While an interesting manuscript, it undoubtedly created no ripple in the pulmonary vascular disease field, as it described a cohort of individuals with small patella syndrome (SPS) without known cardiopulmonary abnormalities, consistent with prior animal model studies [1, 2]. At that time, SPS was known as a rare autosomal-dominant condition characterised by skeletal dysplasia, including irregular development of the patella and additional anomalies involving the limbs and pelvis. Subsequently, in 2010, geneticists expanded our understanding of the phenotype of subjects with mutations in TBX4 (and perhaps other loci nearby, including TBX2), by describing paediatric cases with a more broadly syndromic condition characterised by variable expression of anomalies, such as skeletal dysplasias (including hand and foot irregularities), developmental delay, hearing loss, congenital heart defects (e.g. patent ductus arteriosus, atrial septal defect, aortic valve defects), and PH (no specific PH-related data was provided) [3, 4]. Again, the pulmonary vascular field, current authors included, failed to take notice. Then, in 2013, KERSTJENS-FREDERIKSE et al. [5], from a paediatric PH specialty centre in the Netherlands, described variations in TRX4 and surrounding loci in six out of 20 paediatric pulmonary arterial hypertension (PAH) cases associated with syndromic anomalies similar to those previously described in TRX4 mutants; overall, their data suggested that TRX4 mutations contribute to the PAH condition in paediatrics. Yet, many in our field retained the impression that TRX4 mutations were more prominent among children with highly “syndromic” features, and thus associated with a niche subgroup of PH in children.

Copyright ©ERS 2020